Free Trial

GENPREX (GNPX) Competitors

GENPREX logo
$0.26 -0.01 (-2.59%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$0.26 +0.00 (+0.76%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GNPX vs. CARA, TENX, LSTA, CYTH, FBLG, KLTO, NNVC, BCAB, SNYR, and CMMB

Should you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), NanoViricides (NNVC), BioAtla (BCAB), Synergy CHC (SNYR), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

GENPREX vs. Its Competitors

Cara Therapeutics (NASDAQ:CARA) and GENPREX (NASDAQ:GNPX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

GENPREX has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Cara Therapeutics' return on equity of -367.97% beat GENPREX's return on equity.

Company Net Margins Return on Equity Return on Assets
Cara Therapeutics-1,099.76% -367.97% -107.43%
GENPREX N/A -664.65%-370.18%

44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of GENPREX shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by company insiders. Comparatively, 8.5% of GENPREX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GENPREX has lower revenue, but higher earnings than Cara Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara Therapeutics$7.14M0.00-$118.51M-$21.01N/A
GENPREXN/AN/A-$21.11MN/AN/A

In the previous week, Cara Therapeutics' average media sentiment score of 0.00 equaled GENPREX'saverage media sentiment score.

Company Overall Sentiment
Cara Therapeutics Neutral
GENPREX Neutral

Cara Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, GENPREX has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500.

Summary

Cara Therapeutics beats GENPREX on 5 of the 8 factors compared between the two stocks.

Get GENPREX News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNPX vs. The Competition

MetricGENPREXMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.24M$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E RatioN/A21.5627.6520.23
Price / SalesN/A283.26419.56119.26
Price / CashN/A41.7026.2128.59
Price / Book1.757.538.035.65
Net Income-$21.11M-$55.14M$3.18B$249.15M
7 Day Performance19.55%4.61%2.93%3.28%
1 Month Performance-8.55%0.90%1.72%3.95%
1 Year Performance-86.16%5.40%34.39%20.98%

GENPREX Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNPX
GENPREX
1.0404 of 5 stars
$0.26
-2.6%
N/A-86.2%$7.24MN/A0.0020Gap Down
CARA
Cara Therapeutics
0.3356 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580News Coverage
Gap Down
High Trading Volume
TENX
Tenax Therapeutics
1.265 of 5 stars
$5.76
-1.5%
$17.50
+203.8%
+89.8%$24.27MN/A-2.329
LSTA
Lisata Therapeutics
2.4857 of 5 stars
$2.90
+3.6%
$15.00
+417.2%
-24.8%$24.12M$1M-1.2630Gap Down
CYTH
Cyclo Therapeutics
N/A$0.72
flat
$0.95
+31.8%
N/A$23.72M$870.73K-0.809
FBLG
FibroBiologics
2.5362 of 5 stars
$0.62
+0.7%
$13.00
+1,989.4%
-87.0%$23.65MN/A0.0010Gap Up
KLTO
Klotho Neurosciences
N/A$1.13
+56.9%
N/AN/A$23.40MN/A0.00N/AAnalyst Upgrade
High Trading Volume
NNVC
NanoViricides
1.0876 of 5 stars
$1.40
flat
N/A-20.0%$22.50MN/A-1.9420
BCAB
BioAtla
2.7283 of 5 stars
$0.40
+3.1%
$5.00
+1,162.6%
-71.2%$22.43M$11M-0.3260News Coverage
Gap Down
SNYR
Synergy CHC
3.7613 of 5 stars
$2.85
+17.3%
$10.00
+250.9%
N/A$22.34M$34.83M0.0040Gap Up
High Trading Volume
CMMB
Chemomab Therapeutics
2.9033 of 5 stars
$1.16
-0.9%
$8.50
+632.8%
+19.8%$22.06MN/A-1.5320

Related Companies and Tools


This page (NASDAQ:GNPX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners